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ABSTRACT
The predictive value of circulating microRNAs (miRNAs) in hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC) has been demonstrated in retrospective
studies, but it has rarely been tested in prospective studies. In a cohort of 373 cancerfree HBV patients with a median follow-up of 4.5 years, we measured the expression
of 24 retrospectively identified HCC-related miRNAs in baseline serum samples. When
we analyzed the prospective associations of miRNA expression with HCC risk using
the Cox proportional hazards model, we found that 15 of the 24 miRNAs exhibited a
significant association with HCC risk. In particular, 7 miRNAs (miR-122, miR-99a, miR331, miR-125b, miR-23b, miR-92a, and miR-26a) were associated with an increased
risk, and 8 miRNAs (miR-652, miR-23a, miR-27a, miR-34a, miR-145, miR-10a, miR150, and let-7f) were associated with a decreased risk. Compared to HBV patients with
a low miRNA-based risk score, those with a high miRNA-based risk score exhibited
a significantly elevated HCC risk in both univariate (hazard ratio [HR] 6.56, 95%
confidence interval [CI] 2.74-15.70) and multivariate (HR 3.57, 95% CI 1.34-9.48)
analyses. The risk score significantly increased the HCC prediction performance of
alpha-fetoprotein (concordance index increased from 0.68 to 0.82, P < 0.0001).
In silico analyses indicated that the genes targeted by the 15 miRNAs are mainly
enriched in the transforming growth factor-beta signaling pathway. Collectively, these
results provide prospective evidence that circulating miRNAs serve as non-invasive
markers for risk prediction of HCC in HBV patients.

most prevalent malignancy and the third leading cause
of cancer death [1, 2]. Chronic hepatitis B virus (HBV)
infection is the most prevalent risk factor for HCC,
accounting for more than 50% of HCC worldwide [3, 4].

INTRODUCTION
Hepatocellular carcinoma (HCC), the major
histological subtype of primary liver cancers, is the fifth
www.impactjournals.com/oncotarget
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HBV-related HCC has grown significantly in the United
States during the past several decades, largely due to the
influx of immigrants from HBV-endemic regions [5].
A recent report indicated that among the more than 40
million Americans born outside of the United States, 1.5
million had chronic HBV infection [5]. More than 60% of
these HBV patients are relatively young and their risks of
developing HCC increase significantly as they age [6]. The
overall 5-year survival rate of HCC is extremely low due
to limited therapeutic options [7], but survival is markedly
improved in patients diagnosed and treated early [2].
These facts highlight the importance of identifying HBV
patients at high-risk of HCC for targeted prevention and
management.
MicroRNAs (miRNAs) play important roles in
a wide range of biological processes [8–10]. MiRNAs
could act as oncogenes or tumor suppressors by targeting
and silencing mRNAs involved in carcinogenesis, and
have been significantly implicated in the initiation and
progression of various human cancers [11, 12]. HCC
tumors exhibited different miRNA expression patterns
compared to normal healthy liver or non-neoplastic
peritumoral tissue, suggesting the potential of using
miRNAs as tissue-based HCC biomarkers [13–16].
Recently, circulating miRNAs in serum or plasma have
shown promise as risk prediction and early detection
markers for HCC because of their stability in circulation,
non-invasive procurement, and ease of detection [13, 17,
18]. Li et al. [19] identified 13 serum miRNAs that could
distinguish HBV-positive HCC cases from healthy controls
and cancer-free HBV cases. Zhou et al. [20] reported
a plasma-based 7-miRNA panel with high diagnostic
accuracy for HCC. The performance of this panel was
independent of disease status and exhibited promising
clinical value in diagnosing early-stage HBV-HCC
patients [20]. Nevertheless, the vast majority of published
studies measured circulating miRNAs from patients
already diagnosed with HCC, especially late-stage HCC.
Thus, whether the alterations of these identified miRNAs
are the cause or consequence of hepatocarcinogenesis
remains undetermined.
Mechanistic studies using animal model or liver
tissue have suggested that aberrant expressions of certain
miRNAs precede HCC development [21, 22]. Two recent
multi-stage studies validated some retrospectivelyidentified circulating miRNAs using prospectively
collected samples [23, 24]; however despite the promising
findings, neither study reported an identical miRNA
signature, even though both studies were conducted in
Chinese HBV-HCC patients. To learn more about miRNA
expression in HCC development, we tested the hypothesis
that the expression profile of serum miRNAs alone, or
combined with alpha-fetoproteins (AFP, a traditional HCC
marker commonly used in current clinical settings), can
prospectively predict HCC development in HBV patients.
Our study took advantage of serum samples that were
www.impactjournals.com/oncotarget

prospectively collected many years before HCC diagnosis
in a unique population of Asian Americans with chronic
HBV infection.

RESULTS
Characteristics of the study population
There were 379 cancer-free HBV patients who met
the 1-year exclusion criteria of being followed for at least
1 year, during which time HCC did not develop. These
exclusion criteria were used to minimize the confounding
effects of undiagnosed HCC patients at study entry. After
excluding 6 patients with a more than 50% failure rate
in the detection of 24 miRNAs expression, 373 patients
with a median age of 43.2 years (interquartile range [IQR]
36.6-50.8 years) were included in the primary prospective
cohort. During a median follow-up of 4.5 years (IQR
2.4-7.8 years), 40 (10.7%) of the 373 patients developed
HCC. The median time to HCC diagnosis was 4.0 years
(IQR 2.0-9.6 years). Compared to the HBV patients
who remained cancer-free during follow up, those who
developed HCC were older (P < 0.0001), more likely to be
ever-smokers (P = 0.0301), cirrhotic (P < 0.0001), and had
high AFP levels (P = 0.0005). The demographics variables
of the study subjects appear in Table 1.

Prospective association of the expression levels of
baseline serum miRNAs with HCC risk
Among the 24 tested miRNAs, miR-98 and miR338-3p were excluded from further analyses due to ≥ 50%
missing values in all patients. Significance Analysis of
Microarrays (SAM) analysis identified 15 differentially
expressed miRNAs that were significantly associated
with HCC risk, including 7 miRNAs (miR-122, miR-99a,
miR-331, miR-125b, miR-23b, miR-92a, and miR-26a)
for which an elevated expression was associated with an
increased risk (risk miRNAs), and 8 miRNAs (miR-652,
miR-23a, miR-27a, miR-34a, miR-145, miR-10a, miR150, and let-7f) for which an elevated expression was
associated with a decreased risk (protective miRNAs)
(Table 2).

A miRNA-based risk score
To assess these significant miRNAs as a panel, a risk
score based on the linear combination of the expression
levels of the 15 miRNAs, weighted by the SAM d-value
(Table 2), was calculated for each patient. Figure 1
delineates the distributions of the risk scores (Figure 1A),
follow-up time (Figure 1B), and serum miRNA expression
levels (Figure 1C) of the 373 HBV patients. Each
patient was then assigned to either a high- or a low-risk
group according to the median cutoff of the risk scores.
Compared to the patients with low-risk scores, those with
2
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Table 1: Characteristics of the study population
Total subjects
(N=373, 100%)

HBV patients who
did not develop HCC
(N=333, 89.28%)

HBV patients who
developed HCC
(N=40, 10.72%)

P value*

≤ Median

172 (46.11)

166 (49.85)

6 (15.00)

<0.0001

> Median

201 (53.89)

167 (50.15)

34 (85.00)

Female

115 (30.83)

108 (32.43)

7 (17.50)

Male

258 (69.17)

225 (67.57)

33 (82.50)

Never

244 (65.42)

224 (67.27)

20 (50.00)

Ever

129 (34.58)

109 (32.73)

20 (50.00)

Never

220 (58.98)

198 (59.46)

22 (55.00)

Ever

153 (41.02)

135 (40.54)

18 (45.00)

No

240 (64.34)

217 (65.17)

23 (57.50)

Yes

133 (35.66)

116 (34.83)

17 (42.50)

No

244 (65.42)

240 (72.07)

4 (10.00)

Yes

129 (34.58)

93 (27.93)

36 (90.00)

≤ Median

181 (48.53)

172 (51.65)

9 (22.50)

> Median

192 (51.47)

161 (48.35)

31 (77.50)

Variables
Age

Gender
0.0533

Smoking status
0.0301

Drinking status
0.5880

Family history of cancer
0.3389

Cirrhosis
<0.0001

AFP
0.0005

HBV: hepatitis B virus; HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein.
*The distributions of host characteristics in HBV patients who developed HCC and who did not were compared by chisquare test.
high-risk scores tended to have more risk miRNAs and
less protective miRNAs, and were more likely to develop
HCC during follow-up (Figure 1).
Compared to the HBV patients with low-risk scores,
those with high-risk scores had a 6.56-fold increased risk
for HCC (95% confidence interval [CI] 2.74-15.70) and
exhibited a significantly higher cumulative incidence of
HCC during follow-up (Plogrank = 1.23×10-6, Figure 2A).
After adjustment for age, gender, smoking status, drinking
status, family history of cancer, cirrhosis status, and AFP
values, the association of the risk score with HCC risk
remained significant (hazard ratio [HR] 3.57, 95% CI
1.34-9.48).
When we further restricted the prospective analyses
to a sub-cohort of patients with a 2-year exclusion

www.impactjournals.com/oncotarget

window (297 HBV patients, including 30 patients who
developed HCC during follow-up), the result of the
sub-cohort analysis (Plogrank = 5.00×10-5, Figure 2B) was
consistent with that of the primary cohort (Figure 2A).
The association between risk scores and HCC risk in the
sub-cohort subjects was statistically significant in both
univariate (HR 5.88, 95% CI 2.24-15.45) and multivariate
analyses (HR 2.96, 95% CI 1.05-8.32).

Prediction performance of the 15-miRNA risk
scores and AFP
We then assessed the prediction performance of the
15-miRNA risk scores and AFP using concordance index
(C-index) [25]. In the primary prospective cohort with the

3
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Table 2: Differentially expressed miRNAs in HBV-HCC patients
ID

d-value

Numerator(r)

Denominator(s+s0)

q-value(%)

miR-122

2.8584

7.0516

2.4669

0

miR-99a

1.8061

2.2889

1.2673

0

miR-331

1.6990

1.7507

1.0305

0

miR-125b

1.6342

1.8521

1.1333

0

miR-23b

1.5654

1.4624

0.9342

0

miR-92a

1.2883

1.3291

1.0317

0

miR-26a

1.0043

1.1242

1.1193

3.63

miR-652

-2.4714

-4.2271

1.7104

0

miR-23a

-2.3286

-3.5700

1.5331

0

miR-27a

-2.2951

-3.2686

1.4242

0

miR-34a

-1.6421

-2.2733

1.3844

0

miR-145

-1.5791

-2.9245

1.8520

0

miR-10a

-1.5007

-2.2113

1.4735

0

miR-150

-1.1032

-1.9654

1.7815

1.95

let-7f

-1.0657

-1.0167

0.9540

1.95

HBV: hepatitis B virus; HCC: hepatocellular carcinoma.
1-year exclusion window, the C-index for the 15-miRNA
risk scores was 0.74 (95% CI 0.66-0.82), based on a 5-year
prediction (Table 3). A statistically significant increase in
C-index was observed when 15-miRNA risk scores were
incorporated into the model including AFP values only
(0.68 for AFP only model vs. 0.82 for the model including
miRNA risk scores plus AFP values, P < 0.0001). The
sub-cohort analysis of patients with the 2-year exclusion
window showed very similar results (Table 3).

Development and Function” (Figure 3B). Functional
descriptors assigned by the Ingenuity Knowledge Database
to the molecules in the top network include organismal
death, cancer, cell death, and apoptosis.

DISCUSSION
Aberrant expression of circulating miRNAs has
been observed in HCC patients in retrospective studies,
but it has rarely been tested in a prospective setting. In this
study we demonstrated that a signature of 15 circulating
miRNAs could prospectively predict HCC development in
HBV patients, suggesting that these circulating miRNAs
may be candidates for next-step validations as promising
HCC risk predictors.
Recent studies identified differentially expressed
circulating miRNAs in HCC patients that could separate
HCC patients from cancer-free HBV patients [19, 20, 23,
24, 26, 27]. However, most studies adopted a retrospective
design that used blood samples collected at or after HCC
diagnosis. Therefore, their conclusions were significantly
constrained by the reverse-causation limitation that is
inherent in most retrospective studies. Our prospective
analyses with a 1-year exclusion window circumvented the
reverse-causation limitation. Using blood samples collected
before HCC diagnosis, we demonstrated the prospective
predictive value of a panel of circulating miRNAs,
including miR-92a and miR-145, the two miRNAs which
were recently validated in two Chinese cohorts [23, 24]. To

In silico analyses for potential functions of the
genes regulated by the 15 significant miRNAs
A total of 540 potential target genes were identified
in the four algorithms of TargetScan, miRanda, miRDB,
and PicTar. The Ingenuity Pathway Analysis (IPA)
analysis suggested that cancer (P = 9.88×10-16-1.99×10-4)
and gastrointestinal disease (P = 4.97×10-12-1.27×10-4)
ranked as the top two diseases that were associated
with these target genes. The top five enriched canonical
pathways are shown in Figure 3A. The transforming
growth factor-beta (TGF-β) signaling pathway was the
most significant pathway regulated by these genes (P =
5.14×10-8). Molecular and cellular functions related to
these genes include cell growth and proliferation, cellular
development, gene expression, cell morphology, and cell
death and survival. Moreover, the top network identified
with this method was defined as “Cell-To-Cell Signaling
and Interaction, Tissue Development, Nervous System
www.impactjournals.com/oncotarget
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minimize the confounding effect of patients who actually
had HCC but were not diagnosed at study entry, we further
restricted the analyses to a sub-cohort of patients with a
2-year exclusion window. This more stringent analysis
yielded very similar results, further substantiating the
prospective value of our circulating miRNA signature.
The differential miRNAs expressions between HBV
and HCC patients in our patient cohort are consistent
with previous functional studies. MiR-92a is commonly

considered an onco-miRNAs because it up-regulates
angiogenesis and increases cell proliferation [28].
Several studies have detected significantly high levels of
circulating miR-92a in HBV-related HCC patients [19,
24, 29], consistent with our findings. Let-7a, the most
important member of the let-7 tumor suppressor family,
inhibits HCC cell proliferation via down-regulating signal
transducer and activator of transcription 3 and c-myc, and
up-regulating p16INK4A [30, 31]. In line with our findings, a

Figure 1: Risk score analyses of 373 HBV patients. A. Risk score distribution, X-axis represents patients, and each dot in the blue

line represents the risk score for each patient; B. The status of HBV patients with/without hepatocellular carcinoma (HCC) and follow-up
time, red triangles indicate HCC patients, and black dots indicate cancer-free HBV patients; C. Color-gram of miRNA expression profiles
of HBV patients, rows represent miRNAs, and columns represent patients.
www.impactjournals.com/oncotarget
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recent study [19] showed that 3 serum miRNAs, including
let-7f, could separate HBV-HCC cases from controls.
MiR-122, the most abundant liver-specific miRNA, is
considered a suppressor of cell proliferation and malignant
transformation of hepatocytes with remarkable tumor
inhibition activity [32–34]. Interestingly, although downregulation of miR-122 was frequently reported in the HCC
tumor tissues [2, 34, 35], Qi et al. [36] showed that miR122 in serum was elevated in HCC patients and markedly
reduced in post-operative serum samples, which is
consistent with the observation in our study. The paradox
of miR-122 expression in blood and tissues may be
attributed to the increased release of miRNAs from tumor
cells into blood [13], and needs further investigation.
AFP is currently the only non-invasive circulating
marker for HCC screening, but it has limited sensitivity
and specificity [13, 37]. Identification of novel noninvasive markers that complement AFP is important
to the early detection of HCC. Our results showed that
serum miRNAs significantly improved the prediction
performance of AFP (Table 3). During a 5-year followup period, miRNA risk scores identified 15 of 16 patients
(94%) who were misclassified as cancer-free patients by
AFP, significantly improving sensitivity (data not shown).
In contrast, among the 57 patients who were misclassified
as having HCC due to high AFP values, miRNA risk scores
correctly re-classified 33 (58%), reducing false positive
findings. Nonetheless, although miRNA risk scores
significantly increased the sensitivity of HCC prediction,
they did not significantly improve specificity, as evidenced
by the large number of cancer-free HBV patients with high

risk scores (Figure 1B). This was consistent with findings
from recent prospective studies that reported miRNA
signatures with high sensitivity and low specificity [23,
24]. Efforts are needed to identify additional miRNAs
in order to further reduce false positives and increase
specificity in HCC prediction.
Whether miRNAs behave as oncogenes or tumor
suppressor genes depends on the cellular functions
of their target genes [13, 38]. We conducted in silico
analyses and found that the TGF-β signaling pathway is at
the top of the list of canonical pathways regulated by the
significant miRNAs identified in our study. TGF-β protein
modulates a broad spectrum of cellular processes [39], has
dual regulatory functions in the immune system, and is
activated in response to viral infection, such as HBV [40].
Indeed, an initial step triggering HCC in HBV-infected
patients is epithelial-to-mesenchymal transformation,
which is modulated by TGF-β [41]. The inhibition of
TGF-β is directed against some of the most fundamental
pathological events which lead to chronic liver disease
and subsequently to HCC [42]. Echoing these reports, our
data highlighted the importance of the TGF-β signaling
pathway in HCC initiation, suggesting a potential link
between aberrant miRNA expression, TGF-β, and HCC
development in HBV patients. Functional studies are
warranted to further elucidate the biological mechanisms
underlying these observations.
Our study has several strengths. It is among the
very few studies to analyze circulating miRNAs in
HCC development using a prospective design, which
allows it to bypass the reverse-causation limitation that

Figure 2: 15-miRNA risk scores associated with the risk of HBV-related hepatocellular carcinoma (HCC). The cumulative
incidence of HCC in HBV patients at a high (red line) or a low (blue line) risk group based on the median cutoff of risk scores were plotted
using the Nelson-Aalen method in patients with a A. 1-year or B. 2-year exclusion window.
www.impactjournals.com/oncotarget
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Table 3: Discriminatory accuracy for predicting the development of HCC within 5 years
5-year risk prediction

C-index (95% CI)

1-year exclusion window
miRNA risk scores only

0.74 (0.66-0.82)

AFP values only

0.68 (0.58-0.78)

miRNA risk scores plus AFP values

0.82 (0.74-0.89)

2-year exclusion window
miRNA risk scores only

0.75 (0.66-0.83)

AFP values only

0.66 (0.53-0.79)

miRNA risk scores plus AFP values

0.83 (0.76-0.90)

HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; CI: confidence interval; C-index: concordance index.
is inherent in retrospective studies. The vast majority of
our patients were infected with HBV at birth or childhood,
making our population an ideal cohort to study the longterm risk of HCC development associated with HBV
infection. The study was restricted to patients of Korean
ancestry to eliminate the potential confounding effects of
patient ethnicity. There are also limitations in our study.
Firstly, rather than conducting a comprehensive genomewide profiling using miRNA microarray or small RNA
sequencing, we used a candidate approach to select
promising miRNAs based on the findings of previous
studies. Although cost-effective, this approach might
miss novel important miRNAs not identified in previous
studies. This limitation may account for the low specificity

of the miRNA risk score observed in our study, and could
be remedied in the future by adding more significant
miRNAs to the score. Secondly, given the potential
interindividual, intraindividual, analytic, and preanalytic
variations that may affect circulating miRNA levles
[43], detecting miRNA expression using blood samples
collected at only one time point, although routinely used
in population studies [24, 44, 45], may introduce sample
selection bias. Thirdly, we used cancer-free HBV patients,
instead of HBV-free healthy subjects, as controls in this
study, which may limit the generalization of our findings.
Fourthly, malignant transformation induced by chronic
HBV infection is a multistage pathogenic process and
involves multiple risk predictors [37]. Several variables

Figure 3: In silico analyses for potential functions of the genes regulated by the 15 significant miRNAs. A. The top five

enriched canonical pathways implicated in miRNA-mediated HCC development and B. the top-ranked network formed by predicted
miRNA target genes and functionally related molecules were identified.
www.impactjournals.com/oncotarget
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usually collected in population studies were not recorded
in our medical charts, such as dietary intake, occupational
exposure, physical activity, and socioeconomic status.
However, the majority of host factors that are consistently
associated with HBV progression and HCC risk were
available from our charts. Finally, despite the many
strengths and unique prospective nature, our study has a
relatively small number of patients who developed HCC
and thus our findings need to be validated using larger and
independent prospective patients cohorts.
In conclusion, using a prospective approach to
analyze circulating miRNAs in baseline serum samples
collected at least 1 year before HCC diagnosis, we
identified aberrant serum miRNA expressions that were
associated with HBV-related HCC risk. Our findings
suggested that circulating miRNAs may serve as noninvasive biomarkers for the risk prediction of HCC in
HBV patients.

Blood samples were drawn from each patient when taking
clinical laboratory testing.

MATERIALS AND METHODS

We conducted a comprehensive literature review
to select candidate miRNAs to be included in this study.
Literatures were identified by searching PubMed using
keywords “microRNA”, “serum”, “plasma, “circulating”,
and “HCC” to identify studies that reported miRNAs
related to the risk prediction and early detection of
HCC. Additional studies were identified and supplied
by checking the references of these original studies and
related review articles. We excluded the publications that
were 1) unrelated to miRNA expression, 2) unrelated
to HCC risk, 3) related to HCV-HCC only, 4) related
to miRNA expression in liver tissues only. Finally, we
identified eight references (by 2014) on serum or plasma
miRNA profiling in HBV/HCC patients [13, 19, 20, 34,
36, 37, 47, 48]. We then selected candidate miRNAs
following the criteria: 1) miRNAs were expressed in
human serum or plasma samples; and 2) the expression
levels of miRNAs were significantly different between
cancer-free HBV patients and HBV-related HCC patients.
We selected a total of 24 miRNAs (let-7a, let-7c, let-7f,
miR-10a, miR-21, miR-23a, miR-23b, miR-26a, miR27a, miR-34a, miR-92a, miR-98, miR-99a, miR-122,
miR-125b, miR-145, miR-150, miR-223, miR-331, miR342-3p, miR-375, miR-338-3p, miR-423-3p, and miR652) to determine their expression levels and explore their
prospective association with HCC risk.

Total RNA isolation
Total RNA was isolated from 400 μL serum samples
using the miRNeasy Mini Kit (Qiagen) according to the
manufacturer’s protocol. To allow for normalization of
sample-to-sample variation in RNA isolation, synthetic
C. elegans miRNAs cel-miR-39 and cel-miR-54 (RNA
oligonucleotides synthesized by Qiagen) were added to
each sample [17, 34, 46]. The concentration of total small
RNA molecules was quantified by a Qubit Fluorometer
(Life Technologies). The integrity and size distribution of
the total small RNAs were analyzed using the small RNA
chip on a Bioanalyzer 2100 (Agilent).

Selection of miRNAs to be tested in this study

Study population
This prospective study was based on an existing
and ongoing clinic-based cohort established in 1988
at the Liver Disease Prevention Center of the Thomas
Jefferson University Hospital. Patients who visited the
Center for treatment of liver-related diseases, including
HCC, were consecutively enrolled [6]. There were no
restrictions on age, gender, and disease etiology in patient
recruitment. Approximately 90% of the patients had
HBV infection, and over 90% were of Korean ancestry.
Our study only included cancer-free HBV patients and
HBV-related HCC patients of Korean ancestry in order
to eliminate the confounding effects of population
stratification and disease etiology. The patients included
in the primary prospective cohort also met the following
additional criteria: 1) had a 1-year exclusion window;
2) had baseline blood samples collected at least 1 year
before the diagnosis of HCC; 3) had available major
demographic and clinical data. This study was approved
by the Institutional Review Board at Thomas Jefferson
University.

Epidemiological and clinical data collection

Determination of miRNA expression levels

Demographic and clinical data were collected for
each patient from medical chart review and consultation
with the treating physicians. Demographic variables
included age, gender, ethnicity, smoking status, drinking
status, cirrhosis, and family history of cancer. Ever
smokers and drinkers were defined as described previously
[6]. Liver cirrhosis and HCC were diagnosed by the
combination of clinical diagnosis and imaging techniques
(ultrasound, computed tomography, or magnetic resonance
imaging), complemented by blood markers such as AFP.
www.impactjournals.com/oncotarget

The expression levels of selected miRNAs were
quantitated using quantitative real-time PCR (qRT-PCR)
assay as described previously [17, 49]. Briefly, purified
serum RNA with a fixed volume was reverse transcribed
using the TaqMan miRNA Reverse Transcription Kit and
miRNA-specific stem-loop primers (Applied Biosystems,
CA, USA) using an Eppendorf Thermal Cycler at 16°C for
30 min, 42°C for 30 min, and 85°C for 5 min. The 6 μL
of PCR reaction included 2 μL of diluted (1:10) reverse
8
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transcription product, 3 μL of TaqMan 2X Universal
PCR Master Mix, 0.3 μL of 20X TaqMan miRNA Probe
Assay, and 0.7 μL of nuclease-free water. Real-time PCR
was carried out on a ViiA 7 real-time PCR platform (Life
Technologies) at 95 °C for 10 min, followed by 40 cycles
of 95°C for 15 sec and 60°C for 1 min in a 384-well
plate. All samples were run in duplicate. To ensure the
reliability of experimental data, several negative controls,
including no-template, no reverse-transcriptase, and noreaction buffer negative controls were added in the reverse
transcription phase, and no-template, water-template, no
polymerase, and no-reaction buffer negative controls were
added in the PCR phase. The C. elegans miRNAs were
used as positive controls [17]. The raw cycle threshold
(Ct) value for each miRNA was normalized to the raw
Ct value for spike-in C. elegans miRNAs obtained from
each individual sample to eliminate potential variations
introduced from the processes of RNA isolation and
quantification [49].

genes of these miRNAs were in silico predicted using
four miRNA target prediction algorithms, including the
TargetScan (http://www.targetscan.org), miRanda (http://
www.microrna.org/microrna/home.do), miRDB (http://
mirdb.org/miRDB), and PicTar (http://pictar.mdc-berlin.
de). We compiled the target genes that are predicted by
all of the four databases, and explored their functional
interrelatedness using the IPA software (Ingenuity
Systems, Redwood City, CA). Top-ranked pathways that
are implicated in miRNA-mediated HCC development
were determined based on the incidence of predicted
miRNA targets in a list of canonical pathways provided by
IPA. This software also generated the top-ranked networks
comprising of the predicted miRNA targets. The biological
functions associated with these networks were curated
through Gene Ontology [53]. Fisher’s exact test was used
to calculate a P value determining the significance of the
probability of the association between the genes in the
dataset and the canonical pathways.

Identification of differentially expressed miRNAs

Statistical analyses

Using Relative Quantification Software version
2.3 (Life Technologies), the Ct values of miRNAs were
determined using default threshold settings and the mean
Ct was calculated. Data points that generated duplicated
Ct values with more than one cycle variance were
repeated. The delta Ct values were defined as the mean
Ct value for a specific miRNA in an individual sample
minus the averaged Ct value of spike-in synthetic C.
elegans miRNAs for the same sample. Those miRNAs
with ≥ 50% missing values (miR-98 and miR-338-3p)
were excluded from further analysis. The delta Ct values
were then log2 transformed and median centered by arrays
using the adjusting data function of Cluster 3.0 software
for cluster analysis (Stanford University). The significant
differentially expressed miRNAs between HBV patients
with and without HCC development were identified using
SAM (version 4.0) [50]. SAM gives estimates of the false
discovery rate (FDR), which is the proportion of genes
likely to have been false positively identified by chance
as being significant. The effect of multiple comparisons
was controlled through FDR [51]. In our study, FDR
was estimated with 5000 permutations (the maximum
permissible number), with a threshold of ≤ 5% as being
significant. Unsupervised hierarchical clustering using
Euclidean distance and Centroid linkage in Cluster 3.0 was
carried out to cluster variables into groups based on their
similarity, and the results were visualized in a dendrogram
by Java TreeView version1.1.6r4 [52].

The clinical outcome analyzed in this study was
the diagnosis of HCC. Time to the event was defined as
the time from blood sample taken to the date of HCC
diagnosis (for HCC patients), or last follow-up (for
cancer-free HBV patients). All patients included in this
study had been followed for at least 1 year and had not
developed HCC within this 1-year follow-up (1-year
exclusion window). To minimize the confounding effect
of any patient who had undiagnosed HCC at baseline
sample collection, we further restricted the analyses to
a sub-cohort of patients with a 2-year exclusion window
(followed for at least 2 years and had not developed HCC
within these 2 years). Chi-square testing was used to
compare the distributions of host characteristics in HBV
patients who developed HCC and those who did not. To
analyze the significant miRNAs as a panel, we assigned
each patient a risk score that was developed based on a
linear combination of the expression levels of the miRNAs
multiplied by the SAM d-values, and then used the median
risk score in cancer-free HBV patients as the cutoff point
[44, 49, 54]. The cumulative incidence of HCC by followup years was plotted using the Nelson-Aalen method, and
the difference between the patients with high- and low-risk
scores was compared using log-rank test. The association
between miRNAs risk scores and HCC risk was estimated
using HR with 95% CI calculated by a univariate and
multivariate Cox proportional hazards model, adjusting
for age, gender, smoking status, drinking status, family
history of cancer, cirrhosis status, and AFP values.
Discrimination accuracy for predicting the development
of HCC within 5 years after the baseline blood sample
collection using miRNAs risk scores (alone or combined
with baseline AFP) was evaluated by the C-index. The
differences in discrimination accuracy between different

miRNAs target prediction, pathway analysis,
and network analysis
To explore the molecular functions of the significant
miRNAs identified in our study, the potential target
www.impactjournals.com/oncotarget
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models (miRNA scores with and without AFP) were
assessed by 10,000 bootstrap resampling. SAS (version
9.3, SAS Institute, Cary, NC) and STATA (version 11.0,
STATA Corp., College station, TX) software packages
were used for these analyses. All P values were 2-sided,
with a P value of less than 0.05 considered the threshold
for statistical significance.

10. Huntzinger E, Izaurralde E. Gene silencing by microRNAs:
contributions of translational repression and mRNA decay.
Nat Rev Genet. 2011; 12:99-110.
11. Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of
novel oncogenes and tumor suppressors in hepatocellular
carcinoma. Semin Liver Dis. 2010; 30:75-86.
12. Calin GA, Croce CM. MicroRNA signatures in human
cancers. Nat Rev Cancer. 2006; 6:857-866.
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